ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: Aug 7, 2025, 4:00 PM
2.010
-0.040 (-1.95%)
Pre-market: Aug 8, 2025, 8:04 AM EDT

Company Description

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.

The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs.

In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.

The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V.
ProQR Therapeutics logo
CountryNetherlands
Founded2012
IPO DateSep 18, 2014
IndustryBiotechnology
SectorHealthcare
Employees166
CEODaniel de Boer

Contact Details

Address:
Zernikedreef 9
Leiden, 2333 CK
Netherlands
Phone31 88 166 7000
Websiteproqr.com

Stock Details

Ticker SymbolPRQR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
CIK Code0001612940
CUSIP NumberN71542109
ISIN NumberNL0010872495
SIC Code2834

Key Executives

NamePosition
Daniel Anton de BoerFounder, Chief Executive Officer and Member of Management Board
Dr. Gerard Platenburg Ph.D.Co-Founder, Chief Scientific Officer and Member of Management Board
Dr. Domenico Valerio Ph.D.Founder and Independent Member of Supervisory Board
Dennis HomChief Financial Officer
Sheila SponseleeChief People and Operations Officer
Sarah Cue KielyVice President of Investor Relations and Corporate Communications
Dr. Cristina Lopez Lopez M.D., Ph.D.Chief Medical Officer
Sandra van der KolkJunior Financial Controller

Latest SEC Filings

DateTypeTitle
Aug 7, 20256-KReport of foreign issuer
Jun 26, 20256-KReport of foreign issuer
Jun 3, 20256-KReport of foreign issuer
May 28, 2025SCHEDULE 13DFiling
May 12, 2025SCHEDULE 13G/AFiling
May 8, 20256-KReport of foreign issuer
May 1, 20256-KReport of foreign issuer
Apr 14, 20256-KReport of foreign issuer
Mar 25, 2025EFFECTNotice of Effectiveness
Mar 25, 2025424B5Filing